Precision Medicine in Oncology®

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Luis E. Raez, MD, FACP, FASCO, dives into evolving practices in molecular testing for patients with lung cancer.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

The FDA has granted breakthrough therapy designation to elironrasib for KRAS G12C–mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.

Osimertinib plus chemotherapy improved overall survival in the first-line treatment of advanced non–small cell lung cancer harboring EGFR mutations.

The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.

Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.

Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

The FDA approved Dato-DXd for previously treated, locally advanced or metastatic, EGFR-mutated non–small cell lung cancer.

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.